Jakob Hauge Mikkelsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jakob Hauge Mikkelsen has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Claus Oxvig
Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark
7 shared publications - Christian Brix Folsted Andersen
Department of Biomedicine, Aarhus University, Aarhus, Denmark
6 shared publications - Bent Deleuran
Department of Biomedicine Aarhus University Aarhus Denmark
5 shared publications - Lisbeth Schmidt Laursen
Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
3 shared publications - Stinne Ravn Greisen
Aarhus University
3 shared publications Søren Kløverpris
Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark
3 shared publications
Latest Publications
- Open Access
Autoantibodies From Connective Tissue Diseases Penetrate Cells and Exert Functional Properties
Antinuclear antibodies (ANAs) are a hallmark of connective tissue diseases (CTDs) and serve as robust diagnostic biomarkers. Because their cognate antigens are intracellular, ANAs have long been considered non-pathogenic in CTDs. Here, using systemic sclerosis (SSc) associated anti-topoisomerase I antibodies (ATAs) as a model, we provide data challenging this view. We show that ANAs enter living cells, accumulate in nuclei, and engage their intracellular antigen. Nuclear ATAs inhibit topoisomerase I enzymatic activity, induces DNA damage, fibrosis, and, through the STING pathway, activates type I interferon production. We further identify neonatal Fc receptor (FcRn)-dependent intracellular trafficking as a key determinant of ANAs nuclear access and demonstrate that pharmacological FcRn blockade impairs ATAs functionality. These findings reveal a previously unrecognized intracellular effector function of ANAs and establish a mechanistic framework by which ANAs may directly contribute to tissue injury in CTDs.
Open AccessAutoantibodies From Connective Tissue Diseases Penetrate Cells and Exert Functional Properties
Antinuclear antibodies (ANAs) are a hallmark of connective tissue diseases (CTDs) and serve as robust diagnostic biomarkers. Because their cognate antigens are intracellular, ANAs have long been considered non-pathogenic in CTDs. Here, using systemic sclerosis (SSc) associated anti-topoisomerase I antibodies (ATAs) as a model, we provide data challenging this view. We show that ANAs enter living cells, accumulate in nuclei, and engage their intracellular antigen. Nuclear ATAs inhibit topoisomerase I enzymatic activity, induces DNA damage, fibrosis, and, through the STING pathway, activates type I interferon production. We further identify neonatal Fc receptor (FcRn)-dependent intracellular trafficking as a key determinant of ANAs nuclear access and demonstrate that pharmacological FcRn blockade impairs ATAs functionality. These findings reveal a previously unrecognized intracellular effector function of ANAs and establish a mechanistic framework by which ANAs may directly contribute to tissue injury in CTDs.
- Open Access
- 6 May 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-9
Immunoglobulin G and immunoglobulin A anti-Ro52 in plasma and saliva show little association with disease activity in patients with primary Sjögren’s disease
Primary Sjögren's disease (pSjD) is one of the most common autoimmune connective tissue diseases. Sicca symptoms are a hallmark of pSjD. Up to 80% of patients have immunoglobulin G (IgG) anti-Ro52 autoantibodies in their plasma. This study investigates the frequency of IgG and IgA anti-Ro52 autoantibodies in plasma and saliva from pSjD patients, and assess the associations between disease activity and autoantibody titers. The study was conducted on a Norwegian cross-sectional SjD cohort (n = 113). IgA and IgG anti-Ro52 autoantibodies were measured in plasma and saliva by an indirect in-house enzyme-linked immunosorbent assay (ELISA). ELISA results were correlated with clinical data using relative risk and Spearman's correlation coefficients. Measuring plasma, 73% of the cohort were positive for IgG anti-Ro52 and 47% for IgA anti-Ro52 autoantibodies. In saliva, 34% were positive for IgA anti-Ro52 and 17% for IgG anti-Ro52 autoantibodies. We observed an inverse correlation between plasma IgG anti-Ro52 autoantibodies and disease activity. Patients with a low plasma titre of IgG anti-Ro52 autoantibodies had a higher probability of reporting pain, as indicated by the EULAR Sjögren's Syndrome Patient Reported Index score (relative risk = 0.48, 95% confidence interval 0.29-0.80, p = 0.002). Furthermore, plasma IgA anti-Ro52 correlated significantly with the focus score. IgA and IgG anti-Ro52 autoantibodies in saliva and plasma showed an inverse correlation with disease activity but significant positive association with immune activity in patients with SjD. Our findings do not support the use of salivary IgA and IgG anti-Ro52 autoantibodies as biomarkers of disease activity in SjD.
- 6 May 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-9
Open AccessImmunoglobulin G and immunoglobulin A anti-Ro52 in plasma and saliva show little association with disease activity in patients with primary Sjögren’s disease
Primary Sjögren's disease (pSjD) is one of the most common autoimmune connective tissue diseases. Sicca symptoms are a hallmark of pSjD. Up to 80% of patients have immunoglobulin G (IgG) anti-Ro52 autoantibodies in their plasma. This study investigates the frequency of IgG and IgA anti-Ro52 autoantibodies in plasma and saliva from pSjD patients, and assess the associations between disease activity and autoantibody titers. The study was conducted on a Norwegian cross-sectional SjD cohort (n = 113). IgA and IgG anti-Ro52 autoantibodies were measured in plasma and saliva by an indirect in-house enzyme-linked immunosorbent assay (ELISA). ELISA results were correlated with clinical data using relative risk and Spearman's correlation coefficients. Measuring plasma, 73% of the cohort were positive for IgG anti-Ro52 and 47% for IgA anti-Ro52 autoantibodies. In saliva, 34% were positive for IgA anti-Ro52 and 17% for IgG anti-Ro52 autoantibodies. We observed an inverse correlation between plasma IgG anti-Ro52 autoantibodies and disease activity. Patients with a low plasma titre of IgG anti-Ro52 autoantibodies had a higher probability of reporting pain, as indicated by the EULAR Sjögren's Syndrome Patient Reported Index score (relative risk = 0.48, 95% confidence interval 0.29-0.80, p = 0.002). Furthermore, plasma IgA anti-Ro52 correlated significantly with the focus score. IgA and IgG anti-Ro52 autoantibodies in saliva and plasma showed an inverse correlation with disease activity but significant positive association with immune activity in patients with SjD. Our findings do not support the use of salivary IgA and IgG anti-Ro52 autoantibodies as biomarkers of disease activity in SjD.
- 19 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (11) , 1916-1930
STING signals to NF-κB from late endolysosomal compartments using IRF3 as an adaptor
NF-κB is central for activation of immune responses. Cytosolic DNA activates the cGAS–STING pathway to induce type I interferons (IFNs) and signaling through NF-κB, thus instigating host defenses and pathological inflammation. However, the mechanism underlying STING-induced NF-κB activation is unknown. Here we report that STING activates NF-κB in a delayed manner, following exit from the Golgi to endolysosomal compartments. Activation of NF-κB is dependent on the IFN-inducing transcription factor IRF3 but is independent of type I IFN signaling. This activation pattern is evolutionarily conserved in tetrapods. Mechanistically, the monomer IRF3 is recruited to STING pS358, with delayed kinetics relative to IRF3 recruitment to STING pS366, which promotes type I IFN responses. IRF3 engagement with STING pS358 induces trafficking to late endolysosomal compartments, supporting recruitment of TRAF6 and activation of NF-κB. We identify a TRAF6 binding motif in IRF3 that facilitates recruitment of TRAF6. This work defines a signaling surface on STING and a function for IRF3 as an adaptor in immune signaling. These findings indicate that STING signaling to NF-κB is enabled only within a short time window between exit from the Golgi and lysosomal degradation, possibly limiting inflammation under homeostatic and danger-sensing conditions.
- 19 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (11) , 1916-1930
STING signals to NF-κB from late endolysosomal compartments using IRF3 as an adaptor
NF-κB is central for activation of immune responses. Cytosolic DNA activates the cGAS–STING pathway to induce type I interferons (IFNs) and signaling through NF-κB, thus instigating host defenses and pathological inflammation. However, the mechanism underlying STING-induced NF-κB activation is unknown. Here we report that STING activates NF-κB in a delayed manner, following exit from the Golgi to endolysosomal compartments. Activation of NF-κB is dependent on the IFN-inducing transcription factor IRF3 but is independent of type I IFN signaling. This activation pattern is evolutionarily conserved in tetrapods. Mechanistically, the monomer IRF3 is recruited to STING pS358, with delayed kinetics relative to IRF3 recruitment to STING pS366, which promotes type I IFN responses. IRF3 engagement with STING pS358 induces trafficking to late endolysosomal compartments, supporting recruitment of TRAF6 and activation of NF-κB. We identify a TRAF6 binding motif in IRF3 that facilitates recruitment of TRAF6. This work defines a signaling surface on STING and a function for IRF3 as an adaptor in immune signaling. These findings indicate that STING signaling to NF-κB is enabled only within a short time window between exit from the Golgi and lysosomal degradation, possibly limiting inflammation under homeostatic and danger-sensing conditions.
- Open Access
- 26 May 2025
- Published by Wiley in Hepatology Research
Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis
Background and aims: Sjögren's syndrome is a common comorbidity in patients with primary biliary cholangitis (PBC). Anti‐Ro52 autoantibodies against the protein TRIM21 are often seen in Sjögren's syndrome. TRIM21 consists of four domains (PRY/SPRY, Coiled‐Coil, B‐box, and RING domain), each with a specific function. We hypothesized that patients with PBC and concomitant autoantibodies against TRIM21 had a higher risk of developing Sjögren's syndrome.Methods: Using ELISA, we analyzed plasma from 236 Danish patients with PBC. Binomial regression assessed the risk rates between demographics, serologic variables, PBC‐40 results, and autoantibody positivity.Results: Forty patients (16.9%) tested positive for anti‐Ro52 autoantibodies, with 23 (9.7%) samples positive against Coiled‐Coil, 12 against PRY/SPRY (5.1%), and 10 against RING (4.2%). Increased IgG plasma levels, reports of dry mouth, and a diagnosis of Sjögren's syndrome increased the risk of both anti‐Ro52 and all domain autoantibodies. In the anti‐Ro52 positive subgroup, no less than 14 undiagnosed patients met the criteria for Sjögren's syndrome.Conclusions: We observed a 16.9% positivity of anti‐Ro52 autoantibodies and an association between having these autoantibodies and elevated IgG, the symptom dry mouth, and having Sjögren's syndrome. Furthermore, we found a sizable undiagnosed group of Sjögren's patients in the anti‐Ro52 positive subgroup. Our results suggest that Sjögren's patients are underdiagnosed in patients with PBC. We propose that patients with PBC be tested for anti‐Ro52 autoantibodies and, if positive, referred for rheumatological examination.
- 26 May 2025
- Published by Wiley in Hepatology Research
Open AccessAnti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis
Background and aims: Sjögren's syndrome is a common comorbidity in patients with primary biliary cholangitis (PBC). Anti‐Ro52 autoantibodies against the protein TRIM21 are often seen in Sjögren's syndrome. TRIM21 consists of four domains (PRY/SPRY, Coiled‐Coil, B‐box, and RING domain), each with a specific function. We hypothesized that patients with PBC and concomitant autoantibodies against TRIM21 had a higher risk of developing Sjögren's syndrome.Methods: Using ELISA, we analyzed plasma from 236 Danish patients with PBC. Binomial regression assessed the risk rates between demographics, serologic variables, PBC‐40 results, and autoantibody positivity.Results: Forty patients (16.9%) tested positive for anti‐Ro52 autoantibodies, with 23 (9.7%) samples positive against Coiled‐Coil, 12 against PRY/SPRY (5.1%), and 10 against RING (4.2%). Increased IgG plasma levels, reports of dry mouth, and a diagnosis of Sjögren's syndrome increased the risk of both anti‐Ro52 and all domain autoantibodies. In the anti‐Ro52 positive subgroup, no less than 14 undiagnosed patients met the criteria for Sjögren's syndrome.Conclusions: We observed a 16.9% positivity of anti‐Ro52 autoantibodies and an association between having these autoantibodies and elevated IgG, the symptom dry mouth, and having Sjögren's syndrome. Furthermore, we found a sizable undiagnosed group of Sjögren's patients in the anti‐Ro52 positive subgroup. Our results suggest that Sjögren's patients are underdiagnosed in patients with PBC. We propose that patients with PBC be tested for anti‐Ro52 autoantibodies and, if positive, referred for rheumatological examination.
- Open Access
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
The Cryo-EM structure of human CD163 bound to haptoglobin-hemoglobin reveals molecular mechanisms of hemoglobin scavenging
CD163, a macrophage-specific receptor, plays a critical role in scavenging hemoglobin released during hemolysis, protecting against oxidative effects of heme iron. In the bloodstream, hemoglobin is bound by haptoglobin, leading to its immediate endocytosis by CD163. While haptoglobin’s structure and function are well understood, CD163’s structure and its interaction with the haptoglobin-hemoglobin complex have remained elusive. Here, we present the cryo-electron microscopy structure of the entire extracellular domain of human CD163 in complex with haptoglobin-hemoglobin. The structure reveals that CD163 assembles into trimers (and to some extent dimers), binding haptoglobin-hemoglobin in their center. Key acidic residues in CD163 interact with lysine residues from both haptoglobin and hemoglobin. Calcium-binding sites located near the haptoglobin-hemoglobin interface in CD163 provide explanation for the calcium dependence of the interaction. Furthermore, we show that the interaction facilitating CD163 oligomerization mimics ligand binding and is also calcium dependent. This structural insight into CD163 advances our understanding of its role in hemoglobin scavenging as well as its broader relevance to structurally related scavenger receptors.
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Open AccessThe Cryo-EM structure of human CD163 bound to haptoglobin-hemoglobin reveals molecular mechanisms of hemoglobin scavenging
CD163, a macrophage-specific receptor, plays a critical role in scavenging hemoglobin released during hemolysis, protecting against oxidative effects of heme iron. In the bloodstream, hemoglobin is bound by haptoglobin, leading to its immediate endocytosis by CD163. While haptoglobin’s structure and function are well understood, CD163’s structure and its interaction with the haptoglobin-hemoglobin complex have remained elusive. Here, we present the cryo-electron microscopy structure of the entire extracellular domain of human CD163 in complex with haptoglobin-hemoglobin. The structure reveals that CD163 assembles into trimers (and to some extent dimers), binding haptoglobin-hemoglobin in their center. Key acidic residues in CD163 interact with lysine residues from both haptoglobin and hemoglobin. Calcium-binding sites located near the haptoglobin-hemoglobin interface in CD163 provide explanation for the calcium dependence of the interaction. Furthermore, we show that the interaction facilitating CD163 oligomerization mimics ligand binding and is also calcium dependent. This structural insight into CD163 advances our understanding of its role in hemoglobin scavenging as well as its broader relevance to structurally related scavenger receptors.
- Open Access
- 2 October 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (10) , e009952
Gal-3 blocks the binding between PD-1 and pembrolizumab
Introduction Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignant melanoma (MM) and improved long-term survival. Despite the impressive results, some patients still have progressive disease, and the search for biomarkers predicting response to ICI treatment is ongoing. In this search, galectin-3 (Gal-3) has been suggested as a molecule of interest, both as a marker of treatment response and as a treatment target to potentiate ICI therapy. We have previously demonstrated the binding between programmed cell death 1 (PD-1) and Gal-3, and here, we investigated the interaction between PD-1, pembrolizumab, and Gal-3 in metastatic MM patients. Methods The binding between PD-1, pembrolizumab and Gal-3 was investigated by surface plasmon resonance (SPR) and cryogenic electron microscopy (cryo-EM). The function was studied in in vitro cultures and soluble levels of both PD-1 and Gal-3 were measured in metastatic MM patients, treated with pembrolizumab. Results By SPR, we demonstrated that Gal-3 can block the binding between PD-1 and pembrolizumab, and further visualized a steric inhibition using cryo-EM. T cells cultured with Gal-3 had reduced pro-inflammatory cytokine production, which could not be rescued by pembrolizumab. In patients with metastatic MM, high levels of Gal-3 in plasma were found in patients with a longer progression-free survival in the study period, whereas high Gal-3 expression in the tumor was seen in patients with disease progression. Soluble PD-1 levels in plasma increased after treatment with pembrolizumab and correlated with disease progression. Conclusion We demonstrate that the interaction between PD-1 and Gal-3 interferes with the binding of pembrolizumab, supporting that an immune suppression induced by Gal-3 in the tumor microenvironment cannot be rescued by pembrolizumab.
- 2 October 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (10) , e009952
Open AccessGal-3 blocks the binding between PD-1 and pembrolizumab
Introduction Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignant melanoma (MM) and improved long-term survival. Despite the impressive results, some patients still have progressive disease, and the search for biomarkers predicting response to ICI treatment is ongoing. In this search, galectin-3 (Gal-3) has been suggested as a molecule of interest, both as a marker of treatment response and as a treatment target to potentiate ICI therapy. We have previously demonstrated the binding between programmed cell death 1 (PD-1) and Gal-3, and here, we investigated the interaction between PD-1, pembrolizumab, and Gal-3 in metastatic MM patients. Methods The binding between PD-1, pembrolizumab and Gal-3 was investigated by surface plasmon resonance (SPR) and cryogenic electron microscopy (cryo-EM). The function was studied in in vitro cultures and soluble levels of both PD-1 and Gal-3 were measured in metastatic MM patients, treated with pembrolizumab. Results By SPR, we demonstrated that Gal-3 can block the binding between PD-1 and pembrolizumab, and further visualized a steric inhibition using cryo-EM. T cells cultured with Gal-3 had reduced pro-inflammatory cytokine production, which could not be rescued by pembrolizumab. In patients with metastatic MM, high levels of Gal-3 in plasma were found in patients with a longer progression-free survival in the study period, whereas high Gal-3 expression in the tumor was seen in patients with disease progression. Soluble PD-1 levels in plasma increased after treatment with pembrolizumab and correlated with disease progression. Conclusion We demonstrate that the interaction between PD-1 and Gal-3 interferes with the binding of pembrolizumab, supporting that an immune suppression induced by Gal-3 in the tumor microenvironment cannot be rescued by pembrolizumab.
- 23 February 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 212 (8) , 1334-1344
Trypanosoma brucei Invariant Surface Glycoprotein 75 Is an Immunoglobulin Fc Receptor Inhibiting Complement Activation and Antibody-Mediated Cellular Phagocytosis
Various subspecies of the unicellular parasite Trypanosoma brucei cause sleeping sickness, a neglected tropical disease affecting millions of individuals and domestic animals. Immune evasion mechanisms play a pivotal role in parasite survival within the host and enable the parasite to establish a chronic infection. In particular, the rapid switching of variant surface glycoproteins covering a large proportion of the parasite’s surface enables the parasite to avoid clearance by the adaptive immune system of the host. In this article, we present the crystal structure and discover an immune-evasive function of the extracellular region of the T. brucei invariant surface gp75 (ISG75). Structural analysis determined that the ISG75 ectodomain is organized as a globular head domain and a long slender coiled-coil domain. Subsequent ligand screening and binding analysis determined that the head domain of ISG75 confers interaction with the Fc region of all subclasses of human IgG. Importantly, the ISG75–IgG interaction strongly inhibits both activation of the classical complement pathway and Ab-dependent cellular phagocytosis by competing with C1q and host cell FcγR CD32. Our data reveal a novel immune evasion mechanism of T. brucei, with ISG75 able to inactivate the activities of Abs recognizing the parasite surface proteins.
- 23 February 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 212 (8) , 1334-1344
Trypanosoma brucei Invariant Surface Glycoprotein 75 Is an Immunoglobulin Fc Receptor Inhibiting Complement Activation and Antibody-Mediated Cellular Phagocytosis
Various subspecies of the unicellular parasite Trypanosoma brucei cause sleeping sickness, a neglected tropical disease affecting millions of individuals and domestic animals. Immune evasion mechanisms play a pivotal role in parasite survival within the host and enable the parasite to establish a chronic infection. In particular, the rapid switching of variant surface glycoproteins covering a large proportion of the parasite’s surface enables the parasite to avoid clearance by the adaptive immune system of the host. In this article, we present the crystal structure and discover an immune-evasive function of the extracellular region of the T. brucei invariant surface gp75 (ISG75). Structural analysis determined that the ISG75 ectodomain is organized as a globular head domain and a long slender coiled-coil domain. Subsequent ligand screening and binding analysis determined that the head domain of ISG75 confers interaction with the Fc region of all subclasses of human IgG. Importantly, the ISG75–IgG interaction strongly inhibits both activation of the classical complement pathway and Ab-dependent cellular phagocytosis by competing with C1q and host cell FcγR CD32. Our data reveal a novel immune evasion mechanism of T. brucei, with ISG75 able to inactivate the activities of Abs recognizing the parasite surface proteins.
- 28 June 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (5) , 309-317
Validation of an indirect ELISA assay for assessment of autoantibodies against full-length TRIM21 and its individual domains
Anti-SSA-autoantibodies are common in patients with rheumatologic disease, especially Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis. They consist of both autoantibodies towards Ro60 and Ro52, the latter also known as TRIM21. TRIM21 is an intracellular protein consisting of four domains; PRY/SPRY, Coiled-Coil, B-box and RING. The aim of this study was to establish an indirect ELISA detecting autoantibodies towards both the full-length TRIM21 protein and its four domains. We expressed the five constructs, created, and validated indirect ELISA protocols for each target using plasma from anti-SSA positive patients and healthy controls. Our findings were validated to the clinically used standards. We measured significantly higher levels of autoantibodies towards our full-length TRIM21, and the PRY/SPRY, Coiled-Coil and RING domains in patients compared to healthy controls. No significant difference in the level of autoantibodies were detected against the B-box domain. Our setups had a signal to noise ratio in the range of 30 to 184, and an OD between 2 and 3. Readings did not decline using NaCl of 500 mM as wash, affirming the high binding affinity of the autoantibodies measured. Our protocols allow us to further study the different autoantibodies of anti-SSA positive patients. This creates the possibility to stratify our patients into subgroups regarding autoantibody profile and specific pheno- or endotype.
- 28 June 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (5) , 309-317
Validation of an indirect ELISA assay for assessment of autoantibodies against full-length TRIM21 and its individual domains
Anti-SSA-autoantibodies are common in patients with rheumatologic disease, especially Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis. They consist of both autoantibodies towards Ro60 and Ro52, the latter also known as TRIM21. TRIM21 is an intracellular protein consisting of four domains; PRY/SPRY, Coiled-Coil, B-box and RING. The aim of this study was to establish an indirect ELISA detecting autoantibodies towards both the full-length TRIM21 protein and its four domains. We expressed the five constructs, created, and validated indirect ELISA protocols for each target using plasma from anti-SSA positive patients and healthy controls. Our findings were validated to the clinically used standards. We measured significantly higher levels of autoantibodies towards our full-length TRIM21, and the PRY/SPRY, Coiled-Coil and RING domains in patients compared to healthy controls. No significant difference in the level of autoantibodies were detected against the B-box domain. Our setups had a signal to noise ratio in the range of 30 to 184, and an OD between 2 and 3. Readings did not decline using NaCl of 500 mM as wash, affirming the high binding affinity of the autoantibodies measured. Our protocols allow us to further study the different autoantibodies of anti-SSA positive patients. This creates the possibility to stratify our patients into subgroups regarding autoantibody profile and specific pheno- or endotype.
- Open Access
- 18 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Structure of the proteolytic enzyme PAPP-A with the endogenous inhibitor stanniocalcin-2 reveals its inhibitory mechanism
The metzincin metalloproteinase PAPP-A plays a key role in the regulation of insulin-like growth factor (IGF) signaling by specific cleavage of inhibitory IGF binding proteins (IGFBPs). Using single-particle cryo-electron microscopy (cryo-EM), we here report the structure of PAPP-A in complex with its endogenous inhibitor, stanniocalcin-2 (STC2), neither of which have been reported before. The highest resolution (3.1 Å) was obtained for the STC2 subunit and the N-terminal approximately 1000 residues of the PAPP-A subunit. The 500 kDa 2:2 PAPP-A·STC2 complex is a flexible multidomain ensemble with numerous interdomain contacts. In particular, a specific disulfide bond between the subunits of STC2 and PAPP-A prevents dissociation, and interactions between STC2 and a module located in the very C-terminal end of the PAPP-A subunit prevent binding of its main substrate, IGFBP-4. While devoid of activity towards IGFBP-4, the active site cleft of the catalytic domain is accessible in the inhibited PAPP-A·STC2 complex, as shown by its ability to hydrolyze a synthetic peptide derived from IGFBP-4. Relevant to multiple human pathologies, this unusual mechanism of proteolytic inhibition may support the development of specific pharmaceutical agents, by which IGF signaling can be indirectly modulated.
- 18 October 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Open AccessStructure of the proteolytic enzyme PAPP-A with the endogenous inhibitor stanniocalcin-2 reveals its inhibitory mechanism
The metzincin metalloproteinase PAPP-A plays a key role in the regulation of insulin-like growth factor (IGF) signaling by specific cleavage of inhibitory IGF binding proteins (IGFBPs). Using single-particle cryo-electron microscopy (cryo-EM), we here report the structure of PAPP-A in complex with its endogenous inhibitor, stanniocalcin-2 (STC2), neither of which have been reported before. The highest resolution (3.1 Å) was obtained for the STC2 subunit and the N-terminal approximately 1000 residues of the PAPP-A subunit. The 500 kDa 2:2 PAPP-A·STC2 complex is a flexible multidomain ensemble with numerous interdomain contacts. In particular, a specific disulfide bond between the subunits of STC2 and PAPP-A prevents dissociation, and interactions between STC2 and a module located in the very C-terminal end of the PAPP-A subunit prevent binding of its main substrate, IGFBP-4. While devoid of activity towards IGFBP-4, the active site cleft of the catalytic domain is accessible in the inhibited PAPP-A·STC2 complex, as shown by its ability to hydrolyze a synthetic peptide derived from IGFBP-4. Relevant to multiple human pathologies, this unusual mechanism of proteolytic inhibition may support the development of specific pharmaceutical agents, by which IGF signaling can be indirectly modulated.
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (7) , 1781-1791
The human protein haptoglobin inhibits IsdH-mediated heme-sequestering by Staphylococcus aureus
- 1 February 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (7) , 1781-1791
Open AccessThe human protein haptoglobin inhibits IsdH-mediated heme-sequestering by Staphylococcus aureus